Study drug AUM001 with immunotherapy or chemotherapy for metastatic colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests AUM001 (a targeted drug) combined with either pembrolizumab (an immunotherapy) or irinotecan (a chemotherapy) in people with metastatic colorectal cancer. It aims to shrink tumors and improve outcomes when standard treatments have already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign informed consent.
- You have colorectal cancer that is locally advanced or has spread to other parts of the body (metastatic), confirmed by lab tests.
- You’ve had more than 2 prior treatments for your colorectal cancer (and the prior treatment history must fit the study rules).
- You can provide a tumor tissue sample (existing sample or a new biopsy) from a spot that hasn’t been previously irradiated.
- Your scans show measurable disease, your activity level is good (ECOG 0–1), and you’re expected to live at least 3 months.
- You must have adequate blood/organ function and be able to take oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
This Phase 2 trial tests a chemotherapy combination (liposomal irinotecan), along with TAS-102 and bevacizumab, in people with metastatic colon cancer. It may help if your tumor has mismatch repair–proficient features and you’ve already tried standard colon cancer drugs.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.